Union Bancaire Privee UBP SA Sells 30,201 Shares of Abbott Laboratories $ABT

Union Bancaire Privee UBP SA lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 12.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 220,421 shares of the healthcare product maker’s stock after selling 30,201 shares during the period. Union Bancaire Privee UBP SA’s holdings in Abbott Laboratories were worth $29,979,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC bought a new position in Abbott Laboratories during the 1st quarter worth $28,000. Elequin Capital LP bought a new position in Abbott Laboratories during the 1st quarter worth $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories during the 1st quarter worth $32,000. Finally, Vision Financial Markets LLC bought a new position in Abbott Laboratories during the 1st quarter worth $33,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.4%

Shares of ABT opened at $133.01 on Tuesday. The company has a market capitalization of $231.49 billion, a PE ratio of 16.67, a PEG ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock’s 50-day moving average price is $131.31 and its two-hundred day moving average price is $131.20. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analysts Set New Price Targets

ABT has been the topic of a number of recent research reports. Leerink Partners initiated coverage on Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective on the stock. Wells Fargo & Company lowered their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Raymond James Financial lowered their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Evercore ISI raised their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $145.22.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.